Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential opportunity. Click for more on TECX.

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David Risinger called in his report “the most impressive hemodynamic results we ...

Tectonic Therapeutic shares doubled ... company said that in the overall study population, TX45 achieved a 17.9% reduction in pulmonary capillary wedge pressure, an endpoint known to correlate ...

“I had this paper hung up on my wall for the last four years ... the team has connected the dots to reveal the larger tectonic story. The Denali Fault study has significant implications for ...

In a report released yesterday, Tiago Fauth from Wells Fargo reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report), with a ...